25th May 2021 15:36
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | Barclays PLC. | |
| Company dealt in | WILLIS TOWERS WATSON PLC | |
| Class of relevant security to which the | ORD | |
| dealings being disclosed relate (Note 2) | ||
| Date of dealing | 24 May 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Class of relevant security: | ORD | ||||
Long | Short | ||||
Number | (%) | Number | (%) | ||
(1) | Relevant securities |
|
|
|
|
1,822,484 | 1.41% | 229,733 | 0.18% | ||
|
|
|
| ||
(2) | Derivatives (other than options): |
|
|
|
|
72,359 | 0.06% | 94,581 | 0.07% | ||
|
|
|
| ||
(3) | Options and agreements to |
|
|
|
|
| purchase/sell: | 6,100 | 0.00% | 6,100 | 0.00% | |
|
|
|
| ||
| TOTAL: |
|
|
|
| |
1,900,943 | 1.47% | 330,414 | 0.26% | ||
|
|
|
| ||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
| ||||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale | Number of relevant securities | Price per unit |
Purchase | 1 | 263.7700 USD |
Purchase | 6 | 263.1816 USD |
Purchase | 8 | 264.2200 USD |
Purchase | 71 | 264.2700 USD |
Purchase | 100 | 263.8700 USD |
Purchase | 108 | 264.7000 USD |
Purchase | 190 | 264.1094 USD |
Purchase | 200 | 263.3650 USD |
Purchase | 200 | 263.2400 USD |
Purchase | 220 | 264.6609 USD |
Purchase | 250 | 264.0440 USD |
Purchase | 354 | 264.0878 USD |
Purchase | 521 | 263.5577 USD |
Purchase | 946 | 263.7330 USD |
Purchase | 1,012 | 263.4134 USD |
Purchase | 1,256 | 264.2191 USD |
Purchase | 1,652 | 263.7437 USD |
Purchase | 1,973 | 264.0560 USD |
Purchase | 2,198 | 264.1018 USD |
Purchase | 2,600 | 264.3069 USD |
Purchase | 6,597 | 264.2012 USD |
Purchase | 16,887 | 263.0580 USD |
Purchase | 25,000 | 264.6350 USD |
Purchase | 58,477 | 264.3660 USD |
Purchase | 66,607 | 262.9200 USD |
Sale | 20 | 264.7100 USD |
Sale | 30 | 263.1100 USD |
Sale | 33 | 264.4900 USD |
Sale | 100 | 263.1700 USD |
Sale | 100 | 264.5800 USD |
Sale | 139 | 263.6900 USD |
Sale | 140 | 264.3721 USD |
Sale | 150 | 263.5180 USD |
Sale | 153 | 264.2008 USD |
Sale | 190 | 263.1947 USD |
Sale | 200 | 264.4200 USD |
Sale | 200 | 263.7850 USD |
Sale | 220 | 264.6563 USD |
Sale | 239 | 264.5300 USD |
Sale | 300 | 264.7133 USD |
Sale | 320 | 263.5756 USD |
Sale | 390 | 264.0553 USD |
Sale | 655 | 263.0882 USD |
Sale | 727 | 264.3833 USD |
Sale | 846 | 264.6442 USD |
Sale | 863 | 264.6019 USD |
Sale | 1,000 | 263.4100 USD |
Sale | 1,217 | 264.3337 USD |
Sale | 1,254 | 264.7000 USD |
Sale | 1,256 | 264.2191 USD |
Sale | 1,281 | 264.4565 USD |
Sale | 1,651 | 264.7023 USD |
Sale | 1,820 | 264.0438 USD |
Sale | 2,106 | 263.8075 USD |
Sale | 2,467 | 264.1775 USD |
Sale | 2,979 | 264.1448 USD |
Sale | 4,381 | 264.2228 USD |
Sale | 4,618 | 264.1126 USD |
Sale | 5,014 | 263.7030 USD |
Sale | 7,708 | 264.5875 USD |
Sale | 12,387 | 264.3839 USD |
Sale | 15,016 | 264.1714 USD |
Sale | 17,998 | 263.0890 USD |
Sale | 25,000 | 264.6350 USD |
Sale | 66,607 | 262.9200 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
| Is a Supplemental Form 8 (Open Positions) attached? | YES |
| Date of disclosure: | 25 May 2021 |
| Contact name: | Large Holdings Regulatory Operations |
| Telephone number: | 020 3134 7213 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection |
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
| Product name | Written or | Number of | Exercise | Type | Expiry |
| purchased | relevant securities | price | date | ||
| to which the option | |||||
| or derivative | |||||
| relates | |||||
Put Options | Purchased | -100 | 220.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 100 | 240.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 6,000 | 220.0000 | American | Jul 16, 2021 |
Put Options | Purchased | -6,000 | 200.0000 | American | Jul 16, 2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005722/en/
Copyright Business Wire 2021
Related Shares:
Barclays